China-based Simcere Pharma’s (HKG: 2096) oncology arm, Simcere Zaiming Pharmaceutical, has secured U.S. FDA clearance to initiate a Phase I study of SIM0686. This antibody-drug conjugate (ADC) targets FGFR2b and is designed for patients with locally advanced or metastatic solid tumors.
Innovative ADC Platform
SIM0686 is developed on Simcere’s proprietary ADC platform. It combines an FGFR2b-directed antibody with a topoisomerase inhibitor payload. Preclinical data, presented at AACR 2025, demonstrated potent activity against FGFR2b-positive cells and a bystander effect on adjacent negative cells.
Global Development Acceleration
The FDA’s approval allows Simcere Zaiming to expand its clinical trials globally. The candidate is already in Phase I testing in China, and this latest regulatory nod accelerates its development on the international stage.-Fineline Info & Tech
